Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on NETSCIENTIFIC PLC. We currently have 6 research reports from 2 professional analysts.
|18Nov16 07:00||RNS||Netscientific: Vortex Biosciences Analysis Data|
|03Nov16 04:34||RNS||Vortex Gains CE Mark and FDA Class 1 Registration|
|26Oct16 12:30||RNS||Vortex Biosciences Appoints Non-Executive Director|
|30Sep16 07:00||RNS||ProAxsis Gains CE Mark for its Respiratory Test|
|27Sep16 07:00||RNS||NetScientific Interim Results|
|23Sep16 07:00||RNS||Wanda Technology Selected by 24Hr HomeCare|
|12Sep16 07:00||RNS||Glycotest strengthens IP portfolio|
Frequency of research reports
Research reports on
Transatlantic healthcare technologies
26 Aug 16
NetScientific is a healthcare investment company with a portfolio of digital health, diagnostic, and therapeutic investees. In 2015 the company realigned its investment strategy, bringing a new highly experienced CEO on board, rationalisation of the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p) to accelerate development in some of its key holdings. A series of value inflection points are expected in 2016 and 2017 including Series A financing for four holdings, the commercial ramp of the Wanda digital health platform, and the launch of the Vortex liquid biopsy product.
Transatlantic healthcare technologies
13 Jun 16
NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. 2015 saw significant strategic changes, including senior management restructuring, bringing a new highly experienced CEO on board, rationalisation of the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p). 2016 will be a year for execution and delivery for the portfolio companies on their path to commercialisation, ahead of potential exits from 2017 onwards.
N+1 Singer - Morning Song 05-12-2016
05 Dec 16
RTHM is acquiring a profitable Canadian listed mobile specialist for equivalent of US$42.5m consideration in shares (88.235m). This helps adds to two growth vectors RTHM is targeting; (i) adds unique exclusive audience (10m unique) and (ii) Exclusive demand Yahoo and Facebook. The business has 15 premium and owned and operated apps which provide users with rewards for activity. The business is expected to deliver c$9m of EBITDA in FY18 including $2m of cost synergies. This equates to just 4.7x EV/EBITDA. This marks what we see the first step in RTHM activity to scale the business and deliver on margin potential (see our initiation notes). Our initial estimates for EPS revisions are very significant - for FY18 are 2.3 cents (currently 0.6) and for FY19 4.3 (currently 2.5). There is a call at 830 for investors and we will revise post this.
Panmure Morning Note 02-12-16
02 Dec 16
We expect CareTech to report FY results to September on 8th December. A positive trading update in October indicated that performance for the year was in line with market expectations therefore we are focusing on the outlook. We expect a confident statement since the end of 2016 showed positive trends across fee rates, expansion in places and occupancy. We believe CareTech is well positioned for further expansion, and remains at an attractive valuation. We retain our BUY and 380p price target.
N+1 Singer - Morning Song 06-12-2016
06 Dec 16
With FY16 volume and revenue already disclosed in the pre-close, the focus in today’s prelims is on PBT (£100.3m versus our £101m) and EPS (96.8p versus our 95.4p). No special dividend triggered this year (none forecast) and DPS is held at 46.8p (N1SE: 48.0p). On end markets, recent commentary is reiterated – the core business is growing, whilst consumer electronics will be subdued in the current year (competitive capacity from Solvay). On currency, there will be a material benefit in the current year (a little more than the £14m to £15m previously indicated), and a further tailwind next year if current rates are maintained (quantum TBC). There is also an investment of £10m today in a minority interest in Magma Global, Victrex’ oil and gas mega programme partner. Although the share price is now close to our TP of 1730p, we feel that there is enough in today’s announcement to retain a positive stance on medium term opportunities with strong cashflow and a special dividend potentially to look forward to in the current year.
Panmure Morning Note 05-12-16
05 Dec 16
This week will see Chi-Med present data on both fruquintinib and epitinib at the 17th World Conference on Lung Cancer, concerning two proof-of-concept trials in non-small cell lung cancer (NSCLC). This morning, the poster presentation ‘A Phase I Study of Epitinib To Evaluate Efficacy And Safety In EGFR Mutation Positive (EGFRm+) NSCLC Patients With Brain Metastasis’ is available for investors to view on Chi-Med’s website.
Panmure Morning Note 01-12-16
01 Dec 16
Last month we highlighted the ongoing trajectory of Tuzistra sales, noting the impact of significant investment in the modified marketing strategy for Tuzistra, supported by the step up in sales personnel and increased marketing expenditure. This morning’s AGM statement and trading update gives some further colour on progress.